ClinicalTrials.gg
CompletedNCT03739684CONDORUpdated Jun 14, 2021Results posted

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

A Phase 3 interventional study of 18F-DCFPyL and PET/CT Imaging in Prostate Cancer, Prostate Adenocarcinoma and Prostate Cancer Recurrent, sponsored by Progenics Pharmaceuticals, Inc.. Completed at 14 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Progenics Pharmaceuticals, Inc. (part of Lantheus Holdings, Inc.) · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
208
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing piflufolastat in Prostatic Neoplasms — 5 open to participants now, 10 under way, none of them phase 3. piflufolastat · Prostatic Neoplasms.

Enrollment
5th of 24
208 · median 55
Started
2018
with 3 others
Phase 3
Only one
of the 24
Registered
9th of 24
by date
Lead sponsor
2 of 24
Progenics Pharmaceuticals, Inc.

Among the 24 studies testing piflufolastat in Prostatic Neoplasms, this one is the 5th largest by enrollment, is one of 4 that started in 2018, is the only one in phase 3, and was the 9th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 24 studies testing piflufolastat in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About piflufolastat

piflufolastat: first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing piflufolastat in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.

03

Conditions studied

  • Prostate Cancer
  • Prostate Adenocarcinoma
  • Prostate Cancer Recurrent
  • Prostate Cancer Metastatic

Keywords

  • Positron emission tomography
  • biochemical recurrence
  • rising PSA
  • PET/CT
  • Diagnostic
  • Imaging
  • PSMA
  • radical prostatectomy
  • BCR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male >/= 18 years of age
  • Histopathologically confirmed prostate adenocarcinoma per original diagnosis, with subsequent definitive therapy
  • Suspected recurrence of prostate cancer based on rising PSA after definitive therapy on the basis of:

    1. Post-radical prostatectomy: Detectable or rising PSA that is ≥ 0.2 ng/mL with a confirmatory PSA ≥ 0.2 ng/mL (American Urological Association [AUA]); or
    2. Post-radiation therapy, cryotherapy, or brachytherapy: Increase in PSA level that is elevated by ≥ 2 ng/mL above the nadir (American Society for Therapeutic Radiology and Oncology [ASTRO]-Phoenix)
  • Negative or equivocal findings for prostate cancer on conventional imaging performed as part of standard of care workup within 60 days prior to Day 1
  • ≥6 months as determined by the investigator
  • Able and willing to provide and comply with protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Subjects administered any high energy (>300 KeV) gamma-emitting radioisotope within five (5) physical half-lives prior to Day 1
  • Ongoing treatment with any systemic therapy (e.g. ADT, antiandrogen, GnRH, LHRH agonist or antagonist) for prostate cancer
  • Treatment with ADT in the past 3 months of Day 1
  • Receipt of therapy for prostate cancer within 60 days of Day 1
  • Subjects with any medical condition or other circumstances that, in the opinion of the investigator, compromise the safety or compliance of the subject to produce reliable data or completing the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    18F-DCFPyL Injection

    9 mCi (333 MBq) IV injection of 18F-DCFPyL

    Drug: 18F-DCFPyL · Diagnostic Test: PET/CT Imaging

Interventions

  • A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL

    Also known as: PyL

  • Diagnostic testPET/CT Imaging

    PET/CT imaging will be acquired 1-2 hours post-PyL injection

06

What researchers measure

Primary outcomes

  1. Correct Localization Rate (CLR)

    The Correct Localization Rate (CLR) will be defined as percentage of participants with a one-to-one correspondence between localization of at least one lesion identified on 18F-DCFPyL PET/CT imaging and the composite truth standard. Within 60 days following PyL PET/CT imaging, either biopsy/surgery, conventional imaging, or locoregional radiation therapy of the PyL-suspected lesion(s) will be performed.

    Time frame: Within 60 days following 18F-DCFPyL PET/CT imaging.

Secondary outcomes

  1. Percentage of Participants With a Change in Intended Prostate Cancer Treatment Plans Due to 18F-DCFPyL PET/CT Imaging Results.

    The change in the intended prostate cancer treatment plan will be based on Medical Management Questionnaires completed prior to and after 18F-DCFPyL PET/CT imaging.

    Time frame: Pre 18F-DCFPyL PET/CT imaging and within 60 days following 18F-DCFPyL PET/CT imaging.

  2. The Change From Pre- to Post- 18F-DCFPyl Dosing in Blood Pressure (Safety Outcome Measure)

    The recorded values and their respective changes from the pre-dose values will be summarized using descriptive statistics.

    Time frame: Measured at 2 intervals on the day of dosing; the first interval prior to receiving the 18F-DCFPyL dose and the second interval within 60 to 120 minutes after dosing.

  3. The Change From Pre- to Post- 18F-DCFPyL Dosing in Heart Rate (Safety Outcome Measure)

    The recorded values and their respective changes from the pre-dose values will be summarized using descriptive statistics.

    Time frame: Measured at 2 intervals on the day of dosing; the first interval prior to receiving the 18F-DCFPyL dose and the second interval within 60 to 120 minutes after dosing.

  4. Collection of Concomitant Medications (Safety Outcome Measure)

    Medications will be coded using the WHO drug dictionary. The medications are summarized by ATC level 4 category and presented as number and percentage of participants. Results are presented where the percentage of participants within an ATC level 4 category is \>5.0.

    Time frame: From the time of 18F-DCFPyL dosing to completion of the follow-up visit at 7 (±3) days after 18F-DCFPyL dosing.

  5. Collection of Medical Procedures (Safety Outcome Measure)

    Procedures will be coded using the same version of MedDRA as for medical history. Medical procedures will be displayed as a listing by participant.

    Time frame: From the time of 18F-DCFPyL dosing to completion of the follow-up visit at 7 (±3) days after 18F-DCFPyL dosing.

07

Results

Posted Jun 14, 2021

Participant flow

Participant flow — Overall Study
Milestone18F-DCFPyL Injection
Started208
Completed195
Not completed13

Outcome measures

PrimaryCorrect Localization Rate (CLR)

The Correct Localization Rate (CLR) will be defined as percentage of participants with a one-to-one correspondence between localization of at least one lesion identified on 18F-DCFPyL PET/CT imaging and the composite truth standard. Within 60 days following PyL PET/CT imaging, either biopsy/surgery, conventional imaging, or locoregional radiation therapy of the PyL-suspected lesion(s) will be performed.

Time frame:
Within 60 days following 18F-DCFPyL PET/CT imaging.
Reported as:
Number · percentage of participants
Correct Localization Rate (CLR)
percentage of participants18F-DCFPyL Injection
Central Reader 185.6 (78.8 to 92.3)
Central Reader 287.0 (80.4 to 93.6)
Central Reader 384.8 (77.8 to 91.9)
SecondaryPercentage of Participants With a Change in Intended Prostate Cancer Treatment Plans Due to 18F-DCFPyL PET/CT Imaging Results.

The change in the intended prostate cancer treatment plan will be based on Medical Management Questionnaires completed prior to and after 18F-DCFPyL PET/CT imaging.

Time frame:
Pre 18F-DCFPyL PET/CT imaging and within 60 days following 18F-DCFPyL PET/CT imaging.
Reported as:
Count of participants · Participants
Percentage of Participants With a Change in Intended Prostate Cancer Treatment Plans Due to 18F-DCFPyL PET/CT Imaging Results.
Participants18F-DCFPyL Injection
Percentage of Participants With a Change in Intended Prostate Cancer Treatment Plans Due to 18F-DCFPyL PET/CT Imaging Results.131
SecondaryThe Change From Pre- to Post- 18F-DCFPyl Dosing in Blood Pressure (Safety Outcome Measure)

The recorded values and their respective changes from the pre-dose values will be summarized using descriptive statistics.

Time frame:
Measured at 2 intervals on the day of dosing; the first interval prior to receiving the 18F-DCFPyL dose and the second interval within 60 to 120 minutes after dosing.
Reported as:
Mean · mmHg
The Change From Pre- to Post- 18F-DCFPyl Dosing in Blood Pressure (Safety Outcome Measure)
mmHg18F-DCFPyL Injection
Systolic Blood Pressure: Baseline (actual)138.9 ± 18.61
Systolic Blood Pressure: Post-dosing (actual)136.7 ± 17.15
Systolic Blood Pressure: Change from Baseline-2.2 ± 13.24
Diastolic Blood Pressure: Baseline (actual)78.5 ± 10.18
Diastolic Blood Pressure: Post-dosing (actual)77.3 ± 9.57
Diastolic Blood Pressure: Change from Baseline-1.2 ± 8.20
SecondaryThe Change From Pre- to Post- 18F-DCFPyL Dosing in Heart Rate (Safety Outcome Measure)

The recorded values and their respective changes from the pre-dose values will be summarized using descriptive statistics.

Time frame:
Measured at 2 intervals on the day of dosing; the first interval prior to receiving the 18F-DCFPyL dose and the second interval within 60 to 120 minutes after dosing.
Reported as:
Mean · bpm
The Change From Pre- to Post- 18F-DCFPyL Dosing in Heart Rate (Safety Outcome Measure)
bpm18F-DCFPyL Injection
Heart Rate: Baseline (actual)69.3 ± 12.75
Heart Rate: Post-dosing (actual)65.1 ± 12.09
Heart Rate: Change from Baseline-4.3 ± 7.93
SecondaryCollection of Concomitant Medications (Safety Outcome Measure)

Medications will be coded using the WHO drug dictionary. The medications are summarized by ATC level 4 category and presented as number and percentage of participants. Results are presented where the percentage of participants within an ATC level 4 category is \>5.0.

Time frame:
From the time of 18F-DCFPyL dosing to completion of the follow-up visit at 7 (±3) days after 18F-DCFPyL dosing.
Reported as:
Count of participants · Participants
Collection of Concomitant Medications (Safety Outcome Measure)
Participants18F-DCFPyL Injection
HMG COA REDUCTASE INHIBITORS103
PLATELET AGGREGATION INHIBITORS (EXCLUDING HEPARIN)63
ACE INHIBITORS, PLAIN36
VITAMIN D AND ANALOGUES32
ANGIOTENSIN II ANTAGONISTS, PLAIN31
BETA BLOCKING AGENTS, SELECTIVE31
DIHYDROPYRIDINE DERIVATIVES31
PROTEIN PUMP INHIBITORS29
DRUGS USED IN ERECTILE DYSFUNCTION23
MULTIVITAMINS, PLAIN18
BIGUANIDES17
THIAZIDES, PLAIN16
OTHER ANTIDEPRESSANTS15
ALPHA-ADRENORECEPTOR ANTAGONISTS12
PROPIONIC ACID DERIVATIVES12
THYROID HORMONES11
UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE11
SecondaryCollection of Medical Procedures (Safety Outcome Measure)

Procedures will be coded using the same version of MedDRA as for medical history. Medical procedures will be displayed as a listing by participant.

Time frame:
From the time of 18F-DCFPyL dosing to completion of the follow-up visit at 7 (±3) days after 18F-DCFPyL dosing.
Reported as:
Count of participants · Participants
Collection of Medical Procedures (Safety Outcome Measure)
Participants18F-DCFPyL Injection
Biopsy testes1
Computerized tomogram1
Nuclear magnetic resonance imaging1
Ultrasound testes1
Open reduction of fracture1
Orchidectomy1

Adverse events

Collected over Treatment-emergent adverse events were collected after 18F-DCFPyL administration on Day 1 post-dose through the safety visit 7 (±3) days post-dosing.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
18F-DCFPyL Injection0/208 (0%)1/208 (0.5%)7/208 (3.4%)
Most frequent serious events
Most frequent serious events
Event18F-DCFPyL Injection
HypersensitivityImmune system disorders1/208
HeadacheNervous system disorders1/208
ParesthesiaNervous system disorders1/208
Most frequent other events
Most frequent other events
Event18F-DCFPyL Injection
HeadacheNervous system disorders3/208
FatigueGeneral disorders2/208
HypertensionVascular disorders2/208

Baseline characteristics

Safety population; all participants who received any amount of 18F-DCFPyL

Age, Continuous
Age, Continuous(years)18F-DCFPyL Injection
Median68 (43 to 91)
Sex: Female, Male
Sex: Female, Male(Participants)18F-DCFPyL Injection
Female0
Male208
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)18F-DCFPyL Injection
Asian3
Black or African American15
White188
Other, including not reported2
08

Study locations

14 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Tower Urology
    Los Angeles, California 90048, United States
  • University of California San Francisco - Helen Diller Cancer Center
    San Francisco, California 94143, United States
  • Stanford
    Stanford, California 94305, United States
  • Yale University
    New Haven, Connecticut 06520, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Washington University - Mallinckrodt Institute of Radiology
    Saint Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
  • Chu de Quebec - Universite Laval
    Quebec, G1R2J6, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Aug 2019, 9 months.

Results were first posted in Jun 2021, 1 year 9 months after primary completion. A results delay was requested in Sep 2020.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 9 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2018
First posted
Nov 14, 2018
StartActual
Nov 27, 2018
Primary completionActual
Aug 29, 2019
CompletionActual
Aug 29, 2019
Results delay requested
Sep 16, 2020
Results first posted
Jun 14, 2021
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03739684
Responsible party
Sponsor
First posted
Nov 14, 2018
Start date
Nov 27, 2018
Primary completion
Aug 29, 2019
Completion
Aug 29, 2019
Results posted
Jun 14, 2021
Last update
Jun 14, 2021

Study contacts

Jessica D Jensen
study director · Progenics Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Piflufolastat

Start the discussion